JP2017509351A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509351A5
JP2017509351A5 JP2016561993A JP2016561993A JP2017509351A5 JP 2017509351 A5 JP2017509351 A5 JP 2017509351A5 JP 2016561993 A JP2016561993 A JP 2016561993A JP 2016561993 A JP2016561993 A JP 2016561993A JP 2017509351 A5 JP2017509351 A5 JP 2017509351A5
Authority
JP
Japan
Prior art keywords
genes
biological sample
patient
probes
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016561993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072610 external-priority patent/WO2015103166A1/en
Publication of JP2017509351A publication Critical patent/JP2017509351A/ja
Publication of JP2017509351A5 publication Critical patent/JP2017509351A5/ja
Pending legal-status Critical Current

Links

JP2016561993A 2013-12-30 2014-12-29 前立腺癌遺伝子プロファイル及びその使用方法 Pending JP2017509351A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361921739P 2013-12-30 2013-12-30
US61/921,739 2013-12-30
PCT/US2014/072610 WO2015103166A1 (en) 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same

Publications (2)

Publication Number Publication Date
JP2017509351A JP2017509351A (ja) 2017-04-06
JP2017509351A5 true JP2017509351A5 (enExample) 2018-01-25

Family

ID=53493959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561993A Pending JP2017509351A (ja) 2013-12-30 2014-12-29 前立腺癌遺伝子プロファイル及びその使用方法

Country Status (8)

Country Link
US (1) US20160326594A1 (enExample)
EP (1) EP3090265B1 (enExample)
JP (1) JP2017509351A (enExample)
CN (1) CN106796236A (enExample)
AU (1) AU2014373927B2 (enExample)
CA (1) CA2934828A1 (enExample)
WO (1) WO2015103166A1 (enExample)
ZA (1) ZA201604370B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2017127550A1 (en) * 2016-01-19 2017-07-27 Wayne State University Prostate cancer aggressiveness gene signatures for subjects of african or european descent
CA3062573A1 (en) * 2017-05-12 2018-11-15 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
US11530451B2 (en) * 2018-03-02 2022-12-20 The Johns Hopkins University Methods for prostate cancer detection
CN110054674B (zh) * 2019-03-07 2022-08-05 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap2-19及应用
CN110628908B (zh) * 2019-09-19 2022-05-10 北京恩泽康泰生物科技有限公司 用于前列腺癌诊断分级和良恶性预测的生物标志物及检测试剂盒
JP7784997B2 (ja) * 2020-06-18 2025-12-12 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） 前立腺癌の分子分類器
CN111893177B (zh) * 2020-08-19 2022-10-04 南通大学 遗传性耳聋诱导基因的突变筛选方法及突变检测试剂盒
CN113284559B (zh) * 2021-07-21 2021-10-15 暨南大学 一种物种基因组的启动子查询方法、系统及设备
CN120118995A (zh) * 2024-09-25 2025-06-10 深圳汇芯生物医疗科技有限公司 用于检测前列腺癌生物标志物的引物组、探针组、试剂盒及方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20050032065A1 (en) * 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US10066268B2 (en) * 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
AU2005308594A1 (en) * 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
WO2007035766A2 (en) * 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
US8338109B2 (en) * 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
FR2945820A1 (fr) * 2009-05-25 2010-11-26 Univ Clermont Auvergne Panel de genes pour le pronostic du cancer de la prostate
KR20130043104A (ko) * 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CA3081061C (en) * 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
WO2012024543A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2514836B1 (en) * 2011-04-19 2016-06-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prostate cancer markers
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
SE536352C2 (sv) * 2011-10-24 2013-09-03 Chundsell Medicals Ab Markörgener för klassificiering av prostatacancer
WO2013064636A1 (en) * 2011-11-04 2013-05-10 Noviogendix Research B.V. Combinations of molecular markers in prostate cancer providing a diagnostic tool with improved sensitivity/specificity
US9863002B2 (en) * 2012-06-04 2018-01-09 North Carolina Central University Genetic determinants of prostate cancer risk

Similar Documents

Publication Publication Date Title
Feng et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
DK3013986T3 (en) ASSESSMENT OF PI3K CELL SIGNALING ACTIVITY ACTIVITIES USING MATHEMATICAL MODELING OF TARGET EXPRESSION
Zhang et al. Deep learning promotes profiling of multiple miRNAs in single extracellular vesicles for cancer diagnosis
Bidard et al. Translating metastasis-related biomarkers to the clinic—progress and pitfalls
JP2014531573A5 (enExample)
JP2017507320A5 (enExample)
Varghese et al. Identification and clinical implementation of biomarkers for Barrett's esophagus
JP2013500001A5 (enExample)
WO2008151110A3 (en) Molecular diagnosis and typing of lung cancer variants
JP2013514074A5 (enExample)
ES2603956T3 (es) Método y programa para determinar la sensibilidad a la quimioterapia neoadyuvante para el cáncer de mama
US20160326594A1 (en) Prostate cancer gene profiles and methods of using the same
Annaratone et al. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization
Tao et al. Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review
Verhaegh et al. Knowledge-based computational models
HRP20220128T1 (hr) MARKERI mRNA NA TEMELJU UKUPNE KRVI ZA PREDVIĐANJE RAKA PROSTATE I POSTUPCI ZA OTKRIVANJE ISTOG
JP2016073287A (ja) 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット
RU2011134644A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
Mengual et al. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers
Pedrazzoli Currently debated topics on surgical treatment of pancreatic ductal adenocarcinoma: a narrative review on surgical treatment of borderline resectable, locally advanced, and synchronous or metachronous oligometastatic tumor
JP2016519767A5 (enExample)
Zhang et al. Machine learning-enhanced microfluidic CircRNA detection platform for high-accuracy breast cancer diagnosis
IL317236A (en) Predicting peptide receptor radiotherapy using gene expression testing
Luo et al. Tumor-educated platelets lncRNA-STARD4-AS1 and ELOA-AS1 as potential novel biomarkers for the early diagnosis of non-small cell lung cancer
JP2016086678A (ja) 腎がんの悪性度の検査マーカー及び検査方法